Hims & Hers Health, Inc.
HIMSHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Sep 9, 2026
Scan Results
Daily timeframePart of the healthcare sector, Hims & Hers Health, Inc. (HIMS) is listed under Drug Manufacturers - Specialty & Generic. The company carries a $6.57B market cap, placing it firmly in the mid-cap category. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.
Market Cap
$6.57B
Beta
2.41
P/E (TTM)
—
P/E (Fwd)
36.96
EPS (TTM)
$-0.64
EPS (Fwd)
$0.76
ROE
-32.0%
ROA
-2.2%
Cash
$841.0M
Total Debt
$1.55B
Free CF
$849.4M
52W Change
-42.0%
Annual Financials
Cash vs Debt
Where HIMS stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, HIMS finished 8.72% above its 150-day moving average ($26.38) and 0.77% above its 200-day moving average ($28.46). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is HIMS overbought or oversold?
At the September 3, 2026 close, HIMS's RSI(14) was 49.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $841.0M in cash, though total debt stands at $1.55B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $849.4M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -32.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $526.9M (2022) to $2.35B (2025), reflecting a 346% increase over the period.
Hims & Hers Health, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. No single metric tells the full story. Reviewing HIMS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.